Tesamorelin questions, including “what is tesa?”
A few short answers to the names and timing questions that tend to get tangled together.
What is tesa?
Here, tesa means tesamorelin: a synthetic 44-amino-acid analogue of growth hormone-releasing hormone. Its chemical modification slows breakdown by an enzyme. The early TH9507 pharmacology paper describes the protected signal in laboratory and animal work.
The approved prescription use concerns excess abdominal fat in adults with HIV-associated lipodystrophy. The NIH overview of tesamorelin describes that indication.
What does tesa do?
It stimulates the pituitary to release growth hormone in pulses, followed by increased IGF-1. Human drug-and-hormone modelling traces that response. In the main HIV trial, visceral fat fell while weight and fat beneath the skin changed little.
I’d answer “what does tesa do?” with those anatomical details still attached. The phrase “belly fat” covers more than the visceral compartment measured in the trial.
Tesamorelin mechanism of action
Tesamorelin activates the GHRH receptor on growth-hormone-producing pituitary cells. The gland releases its own hormone; the liver responds with more IGF-1. A small study in healthy men measured the hormonal response over 2 weeks.
The full mechanism account also covers adiponectin, a hormone that failed to change significantly in a related short experiment. That less convenient finding helps me judge how much the proposed metabolic explanation has actually demonstrated.
Half life of tesamorelin
The secondary human estimate is 26–38 minutes. The early non-clinical measurements gave 21–45 minutes in dogs. These figures describe plasma half-life; elevated IGF-1 can outlast the drug’s blood exposure, as described in the human response model.
The tesamorelin half-life page separates those sources and explains why “how long in the system?” has a less precise answer than a half-life number suggests.
Does tesamorelin increase testosterone?
The human hormone study characterizes growth hormone and IGF-1. The evidence described here supports no established testosterone benefit from tesamorelin. I’d want a study that actually measured and supported that outcome before adding it to the list of effects.
Stopping tesamorelin
Visceral fat reaccumulated after withdrawal in the 52-week follow-up. The reduction during continued treatment therefore has a durability condition attached. I consider the withdrawal observation essential to understanding the original result.
The research account follows both periods. Side effects, including fluid-related effects and growth-factor concerns, have their own discussion.